Tofacitib is not indicated for the treatment of ankylosing spondylitis. Tofacitib is a JAK inhibitor indicated for adult patients with moderately to severely active rheumatoid arthritis in whom methotrexate is insufficiently effective or intolerant. Ankylosing spondylitis is a chronic inflammatory disease, and tofacitib indications do not include the treatment of ankylosing spondylitis, therefore tofacitib is not indicated for the treatment of ankylosing spondylitis. Some patients may experience respiratory tract infections, pneumonia and other adverse reactions after using Tofacitib, and it is contraindicated in patients with hypoproteinemia and infectious diseases. If lower back or hip pain occurs, you should immediately go to the hospital, hospital-related examinations, clear diagnosis, and actively cooperate with the doctor’s treatment, do not blindly take the drug.